Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Common Equity (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Common Equity for 2 consecutive years, with $53.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 55.77% to $53.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.4 million through Dec 2025, down 55.77% year-over-year, with the annual reading at $53.4 million for FY2025, 55.77% down from the prior year.
  • Common Equity for Q4 2025 was $53.4 million at Pyxis Oncology, down from $68.8 million in the prior quarter.
  • The five-year high for Common Equity was $184.2 million in Q1 2024, with the low at $53.4 million in Q4 2025.